Literature DB >> 11461121

The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.

R Seidman1, I Gitelman, O Sagi, S B Horwitz, M Wolfson.   

Abstract

Taxol is an anticancer agent of natural origin with significant activity against a number of human cancers including ovarian and breast carcinomas. Its cytotoxic activity has been attributed to its ability to stabilize microtubules and to promote microtubule assembly. Recently it has become clearer that Taxol has additional activities including effects in cell signaling and gene expression. We have shown previously that Taxol activates ERK 1/2 MAP-kinases and results in the formation of GRB2/SHC complexes in murine macrophage-like RAW 267.4 cells. Here we demonstrate that Taxol activates ERK 1/2 and p38 MAP-kinases in human ovarian carcinoma cells with distinct kinetics. Activation of ERK1/2 has been observed at low concentrations of Taxol (1-100 nM) within 0.5-6 h, whereas longer exposure(24 h) to nanomolar concentrations of Taxol resulted in an abrogation of the ERK1/2 phosphorylation/activation. Higher concentrations (1-10 microM) resulted in a sharp inhibition of ERK1/2 activity. p38 kinase was activated by high concentrations (1-10 microM) of Taxol within 2 h and remained active for more than 24 h. The kinetic studies showed that these effects of Taxol coincided with an inhibition of proliferation, and the onset of apoptosis. The appearance of the fragmented chromatin visualized by DAPI staining, and DNA fragments seen on an agarose gel, coincided with the decrease in ERK1/2 activation and concomitant increase of the level of active p38 MAPK. The inhibitor PD98059 abrogated ERK 1/2 activation and increased the cytotoxic effect of Taxol. An inhibitor of p38 kinase, SB203580, protected the cells partially from Taxol and, unexpectedly, activated ERK 1/2 kinases. We conclude that the alternative use of ERK1/2 and p38 MAP-kinase pathways may be necessary for the transition from proliferation state to Taxol-induced apoptosisin human ovarian carcinoma cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461121     DOI: 10.1006/excr.2001.5262

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  23 in total

1.  Angiotensin-(1-7) suppresses the number and function of the circulating fibrocytes by upregulating endothelial nitric oxide synthase expression.

Authors:  Kan Wang; Xiaosheng Hu; Changqing Du; Shike Tu; Furong Zhang; Xudong Xie
Journal:  Mol Cell Biochem       Date:  2012-03-29       Impact factor: 3.396

2.  Non-muscle myosin IIA differentially regulates intestinal epithelial cell restitution and matrix invasion.

Authors:  Brian A Babbin; Stefan Koch; Moshe Bachar; Mary-Anne Conti; Charles A Parkos; Robert S Adelstein; Asma Nusrat; Andrei I Ivanov
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

3.  Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

Authors:  Kuichun Zhu; Elvira Gerbino; Darrin M Beaupre; Paul A Mackley; Carlos Muro-Cacho; Craig Beam; Andrew D Hamilton; Mathias G Lichtenheld; William G Kerr; William Dalton; Melissa Alsina; Saïd M Sebti
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

4.  Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Authors:  Ayesha N Shajahan; Zachary C Dobbin; F Edward Hickman; Sivanesan Dakshanamurthy; Robert Clarke
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

5.  Met interacts with EGFR and Ron in canine osteosarcoma.

Authors:  J K McCleese; M D Bear; S K Kulp; C Mazcko; C Khanna; C A London
Journal:  Vet Comp Oncol       Date:  2011-12-08       Impact factor: 2.613

6.  N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells.

Authors:  H-J Kim; N Chakravarti; N Oridate; C Choe; F-X Claret; R Lotan
Journal:  Oncogene       Date:  2006-05-04       Impact factor: 9.867

7.  ERK5/KLF4 signaling as a common mediator of the neuroprotective effects of both nerve growth factor and hydrogen peroxide preconditioning.

Authors:  Chang Su; Fen Sun; Rebecca L Cunningham; Nataliya Rybalchenko; Meharvan Singh
Journal:  Age (Dordr)       Date:  2014-07-12

8.  Subtype specific roles of mitogen activated protein kinases in L6E9 skeletal muscle cell differentiation.

Authors:  Ashwani Khurana; Chinmoy S Dey
Journal:  Mol Cell Biochem       Date:  2002-09       Impact factor: 3.396

Review 9.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

10.  Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells.

Authors:  Hyun Sun Cho; Seung Hee Chang; Youn Sun Chung; Ji Young Shin; Sung Jin Park; Eun Sun Lee; Soon Kyung Hwang; Jung Taek Kwon; Arash Minai Tehrani; Minah Woo; Mi Sook Noh; Huda Hanifah; Hua Jin; Cheng Xiong Xu; Myung Haing Cho
Journal:  J Vet Sci       Date:  2009-03       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.